Get started
Author

Hassan Gandjini

Observed names: H Gandjini, H. Gandjini
Institution: Pfizer (France)
OpenAlex ID: A5077335209
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
2010 · Antonio T. Freire, Vasyl Melnyk, et al. · Diagnostic Microbiology and Infectious Disease · 286
Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial
2003 · Alexander L. Gerbes, Veit Gülberg, et al. · Gastroenterology · 283
PDF
Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia
2013 · Julio Ramirez, Nathalie Dartois, et al. · Antimicrobial Agents and Chemotherapy · 229
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study
2008 · I. Florescu, M. Beuran, et al. · Journal of Antimicrobial Chemotherapy · 134
Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects.
1993 · L Lagrost, H Gandjini, et al. · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · 134
PDF
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia
2008 · Cristina Tanaseanu, Carlos Bergallo, et al. · Diagnostic Microbiology and Infectious Disease · 112
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae
2008 · K. Vasilev, G. Reshedko, et al. · Journal of Antimicrobial Chemotherapy · 99
Evidence for Nonesterified Fatty Acids as Modulators of Neutral Lipid Transfers in Normolipidemic Human Plasma
1995 · Laurent Lagrost, Emmanuel Florentin, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 61
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
2009 · the 313 Study Group, Cristina Tanaseanu, et al. · BMC Pulmonary Medicine · 55
PDF
Tigecycline Versus Levofloxacin for the Treatment of Community-Acquired Pneumonia: European Experience
2008 · N. Dartois, N. Castaing, et al. · Journal of Chemotherapy · 34
Resistance to LDL oxidative modifications of an N-terminal apolipoprotein B epitope
1991 · Hassan Gandjini, Philippe Gambert, et al. · Atherosclerosis · 10
Tigecycline Versus Levofloxacin in Hospitalized Patients With Community-Acquired Pneumonia: An Analysis of Risk Factors
2013 · Nathalie Dartois, C Angel Cooper, et al. · The Open Respiratory Medicine Journal · 5
PDF
Effect of Acute Glycerol Administration with or without a Mixed Meal in Humans
1995 · N. Nicolaïew, E. Cavallero, et al. · Annals of Nutrition and Metabolism · 4
Composition and immunoreactivity of serum low density lipoproteins (LDL) before and after LDL-apheresis on dextran sulfate-cellulose columns
1994 · Hassan Gandjini, Philippe Gambert, et al. · Transfusion Science · 2
P848 Efficacy of tigecycline (TGC) compared with levofloxacin (LEV) for treating Streptococcus pneumoniae bacteraemia in patients (pts) hospitalised with community-acquired pneumonia (CAP)
2007 · N. Dartois, G. Dukart, et al. · International Journal of Antimicrobial Agents
[Effect of LDL oxidation on the immunoreactivity of human apolipoprotein B].
1992 · H Gandjini, P Gambert · PubMed
Immunoréactivité de l'apolipoprotéine B humaine : variations expérimentales et physio-pathologiques
1991 · Hassan Gandjini · OpenGrey (Institut de l'Information Scientifique et Technique)
Works count: 17
Citation count: 1,448
H-index: 10
I10-index: 11
Year
Topic
Type